Abstract
Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5% are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.
| Original language | English |
|---|---|
| Pages (from-to) | 325-329 |
| Number of pages | 5 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 29 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
- Infectious Diseases
- Medicine(all)
Cite this
Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes : A randomized intraindividual comparison study. / Sotiriou, E.; Apalla, Z.; Vrani, F.; Lallas, A.; Chovarda, E.; Ioannides, D.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 29, No. 2, 01.02.2015, p. 325-329.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes
T2 - A randomized intraindividual comparison study
AU - Sotiriou, E.
AU - Apalla, Z.
AU - Vrani, F.
AU - Lallas, A.
AU - Chovarda, E.
AU - Ioannides, D.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5% are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.
AB - Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5% are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.
UR - http://www.scopus.com/inward/record.url?scp=84921559033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921559033&partnerID=8YFLogxK
U2 - 10.1111/jdv.12538
DO - 10.1111/jdv.12538
M3 - Article
C2 - 24754529
AN - SCOPUS:84921559033
VL - 29
SP - 325
EP - 329
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 2
ER -